Skip to content
value.today

Terns Pharmaceuticals, Inc.

🇺🇸 Foster City, California, USAPharmaceuticalsFounded 2020
Total raised
$98 M
1 round on record
Latest round
$98 M
Dec 2020
First round on record
Dec 2020
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Terns Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2020$98 MNo. 1$50 to $250 million

Terns Pharmaceuticals, Inc.: Raise no. 1, Dec 2020

Investors in this round

13 investors had bought by the notice of Jan 7, 2021: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Terns Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$98 M of $98 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bryan Yoon · Executive Officer
  • Mark Vignola, Ph.D. · Executive Officer
  • Senthil Sundaram · Director, Executive Officer
  • Weidong Zhong, Ph.D. · Executive Officer, Director
  • Carl Gordon, Ph.D. · Director
  • David Fellows · Director
  • Elise Wang · Director
  • Hongbo Lu, Ph.D. · Director
  • Jeffrey Kindler · Director
  • Jill Quigley · Director
  • Yi Shi, Ph.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bryan Yoon, General Counsel. Source: SEC Form D, newest notice filed Jan 7, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Terns Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2021).

    SEC Form D · Jan 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2021

That is all the official record says: Terns Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Terns Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Deerfield Partners, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Hopewell Resources Holdings LtdCompanynot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
LAV Aqua LtdCompanynot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
LAV Biosciences Fund V, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
OrbiMed Advisors III LtdFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
OrbiMed Asia GP III, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
OrbiMed Capital GP VII LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Oriental Spring Venture LtdVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital Surplus Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital VIII, LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 13 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Terns Pharmaceuticals, Inc.
NameRoleNamed in
Bryan YoonExecutive officerJan 2021
Mark Vignola, Ph.D.Executive officerJan 2021
Senthil SundaramExecutive officerJan 2021
Weidong Zhong, Ph.D.Executive officerJan 2021
Carl Gordon, Ph.D.DirectorJan 2021
David FellowsDirectorJan 2021
Elise WangDirectorJan 2021
Hongbo Lu, Ph.D.DirectorJan 2021
Jeffrey KindlerDirectorJan 2021
Jill QuigleyDirectorJan 2021
Senthil SundaramDirectorJan 2021
Weidong Zhong, Ph.D.DirectorJan 2021
Yi Shi, Ph.D.DirectorJan 2021